Clinical Trials


Evidence relating to the therapeutic efficacy of PSK comes from numerous clinical trials conducted on thousands of patients in Japan since 1970.

To date, significant benefits from PSK immunotherapy used in conjunction with surgery and radiation and/or chemotherapy have been indicated for cancer of the stomach, rectum, colon, oesophagus, nasopharynx, breast and lung as demonstrated by the following studies including a meta-analysis.

The results showed that PSK given alone or added to chemotherapy or radiation therapy following surgery significantly improved overall survival and disease-free survival.